Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Peptides and peptide simulacrums to treat pathologies characterized by an inflammatory response

A disease and symptom technology, applied in the field of peptides and peptidomimetics for the treatment of pathologies characterized by inflammatory responses, to solve problems such as accelerated LDL oxidation

Inactive Publication Date: 2008-07-23
RGT UNIV OF CALIFORNIA
View PDF65 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

High-density lipoprotein (HDL) has been found to protect LDL from oxidation, but has been found to accelerate LDL oxidation under certain conditions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptides and peptide simulacrums to treat pathologies characterized by an inflammatory response
  • Peptides and peptide simulacrums to treat pathologies characterized by an inflammatory response
  • Peptides and peptide simulacrums to treat pathologies characterized by an inflammatory response

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

Using ApoJ-related peptides to mediate atherosclerotic symptoms

Inhibit LDL-induced chemotactic activity of monocytes

[0306] Figure 1 shows the effect of D-4F (Anantharamaiah et al. (2002) (2002) Circulation, 105: 290-292) on the inhibition of LDL-induced chemotaxis of monocytes during co-incubation and apoJ prepared with D amino acids Peptide (D-J336, Ac-LLEQLNEQFNWVSRLANLTQG-E-NH 2 , SEQ ID NO: 1177)) Comparison of effects. Human aortic endothelial cells were incubated with medium (not added) only, with control human LDL (200 μg protein / ml) or control human LDL + control human HDL (350 μg HDL protein / ml). Add D-J336 or D-4F in the specified concentration range plus control human LDL (200 μg protein / ml) to other wells. After overnight incubation, the monocyte chemotactic activity of the supernatant was determined. As shown in Figure 1, the in vitro concentration of the apoJ variant peptide that inhibits the chemotactic activity of monocytes induced by LDL induced by human art...

Embodiment 2

Apo E-deficient mice oral G * Peptides increase the protective ability of HDL

[0319] 4-month-old female apoE-deficient mice (n=4 per group) use G with the following amino acid sequence * Peptide treatment: peptide 113-122 = Ac-L V G R Q L E E F L-NH 2 (SEQ IDNO: 9), peptide 336-357=Ac-L L E Q L N E Q F N W V S R L A N L T Q GE-NH 2 (SEQ ID NO: 17) and peptide 377-390 = Ac-PS G V T E V V V K L F DS-NH 2 (SEQ ID NO: 19).

[0320] Each mouse was given 200 μg peptide by gastric tube. After 4 hours, blood was obtained, plasma was separated, lipoprotein was obtained, and the protective ability of HDL (25μg / ml) in human artery wall cell culture against LDL (100μg / ml) oxidation was determined. The data is shown in Figure 8. In mice, the peptide provides significant HDL protection to mice.

[0321] In another experiment, 4-month-old female apoE-deficient mice (n=4 per group) were treated with the 11 amino acid G* peptide 146-156 with the following sequence: Ac-Q Q T H ML D V M Q D-NH 2 (S...

Embodiment 3

Solution phase chemical synthesis of peptides

[0322] In certain embodiments, solution phase synthesis chemistry provides a more economical synthesis method for the peptides of the invention.

[0323] Before the synthesis method of the present invention, a total solid phase synthesis chemistry method is generally used for synthesis. The solid phase synthesis of peptides with less than 9 amino acids is more economical than the solid phase synthesis of peptides with more than 9 amino acids. Due to the separation of the extended amino acid chain on the resin, the synthesis of peptides larger than 9 amino acids resulted in severe material loss. Solid-phase synthesis of peptides containing less than 9 amino acids is more economical because the loss of extended chains on the resin is relatively small.

[0324] In some embodiments, the synthesis of 18 amino acid apoA-I mimic peptides, 4F (and other related peptides) is converted from full solid phase synthesis or conversion to full solu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
depthaaaaaaaaaa
Login to View More

Abstract

The present invention provides novel active agent (eg, peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and / or other pathologies characterized by an inflammatory response. In certain embodiments, the peptide is similar to the G of apolipoprotein J * Amphipathic helix. The active agent is very stable and easy to administer by oral route.

Description

[0001] This application claims the priority and rights of USSN60 / 697,495 filed on July 7, 2005 and USSN60 / 676,431 filed on April 29, 2005. The contents of these two patent documents are incorporated herein by reference in their entirety for all purpose. Statement concerning the right to inventions in the research and development funded by the federal government [0002] This research was partially supported by grant number HL30568 from the Naional Heart Blood Lung Institute of the National Institutes of Health. The US federal government may have certain rights in this invention. Invention field [0003] The present invention relates to the field of atherosclerosis and other diseases characterized by inflammation and / or the formation of various oxidized species. In particular, the present invention relates to the identification of various active agents that can be administered orally and ameliorate one or more symptoms of diseases characterized by an inflammatory response and / or th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00
CPCY02A50/30
Inventor A·M·福格曼M·纳瓦布G·M·阿南塔拉马拉
Owner RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com